The Epidemic of Heart Failure: A Lucid Approach to Stemming the Rising Tide

Canadian Journal of Cardiology

Volumn 30, Issue 12, 2014, Pages S442-S454

  O'Meara, Eileen ^a   Thibodeau Jarry, Nicolas ^b   Ducharme, Anique ^a   Rouleau, Jean Lucien ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIC GMP; INOTROPIC AGENT; MINERALOCORTICOID ANTAGONIST; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

AORTA STENOSIS; CANADIAN; CARDIAC RESYNCHRONIZATION THERAPY; CELL THERAPY; DEVICE THERAPY; EPIDEMIC; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE METABOLISM; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; KIDNEY DENERVATION; MITRAL VALVE REGURGITATION; MORTALITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT CARE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIMARY MEDICAL CARE; PROGNOSIS; REVIEW; TECHNOLOGY; TREATMENT OUTCOME; VAGUS NERVE STIMULATION; CANADA; STATISTICS AND NUMERICAL DATA;

CANADA; HEART FAILURE; HOSPITALIZATION; HUMANS; PROGNOSIS;

EID: 84922592207     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.09.032     Document Type: Review

References (113)

1. Chow C.M., Donovan L., Manuel D., Johansen H., Tu J.V. Regional variation in self-reported heart disease prevalence in Canada. Can J Cardiol 2005, 21:1265-1271.
2. Johansen H., Strauss B., Arnold J.M., Moe G., Liu P. On the rise: the current and projected future burden of congestive heart failure hospitalization in Canada. Can J Cardiol 2003, 19:430-435.
3. Darwin F., Yeung M.D., Nicole K. Trends in the incidence and outcomes of heart failure in Ontario, Canada: 1997 to 2007. CMAJ 2012, 184:E765-E773.
4. Brouwers F.P., de Boer R.A., van der Harst P., et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 2013, 34:1424-1431.
5. Blair J.E., Huffman M., Shah S.J. Heart failure in North America. Curr Cardiol Rev 2013, 9:128-146.
6. Hellermann J.P., Jacobsen S.J., Redfield M.M., et al. Heart failure after myocardial infarction: clinical presentation and survival. Eur J Heart Fail 2005, 7:119-125.
7. Lloyd-Jones D.M., Larson M.G., Leip E.P., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002, 106:3068-3072.
8. Arnlov J., Lind L., Sundstrom J., et al. Insulin resistance, dietary fat intake and blood pressure predict left ventricular diastolic function 20 years later. Nutr Metab Cardiovasc Dis 2005, 15:242-249.
9. Arnlov J., Lind L., Zethelius B., et al. Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up. Am Heart J 2001, 142:720-724.
10. Kenchaiah S., Evans J.C., Levy D., et al. Obesity and the risk of heart failure. NEngl J Med 2002, 347:305-313.
11. Bleumink G.S., Knetsch A.M., Sturkenboom M.C., et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004, 25:1614-1619.
12. He J., Ogden L.G., Bazzano L.A., et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001, 161:996-1002.
13. Djousse L., Driver J.A., Gaziano J.M. Relation between modifiable lifestyle factors and lifetime risk of heart failure. JAMA 2009, 302:394-400.
14. Ledwidge M., Gallagher J., Conlon C., et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013, 310:66-74.
15. Smith G.L., Lichtman J.H., Bracken M.B., et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. JAm Coll Cardiol 2006, 47:1987-1996.
16. Paulus W.J., Tschope C., Sanderson J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007, 28:2539-2550.
17. Senni M., Paulus W.J., Gavazzi A., et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J 2014.
18. Boyde M., Turner C., Thompson D.R., Stewart S. Educational interventions for patients with heart failure: a systematic review of randomized controlled trials. JCardiovasc Nurs 2011, 26:E27-E35.
19. Cowie M.R. Person-centred care: more than just improving patient satisfaction?. Eur Heart J 2012, 33:1037-1039.
20. Ekman I., Wolf A., Olsson L.E., et al. Effects of person-centred care in patients with chronic heart failure: the PCC-HF study. Eur Heart J 2012, 33:1112-1119.
21. Thomas R., Huntley A., Mann M., et al. Specialist clinics for reducing emergency admissions in patients with heart failure: a systematic review and meta-analysis of randomised controlled trials. Heart 2013, 99:233-239.
22. Ducharme A., Doyon O., White M., Rouleau J.L., Brophy J.M. Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial. CMAJ 2005, 173:40-45.
23. Bourge R.C., Abraham W.T., Adamson P.B., et al. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. JAm Coll Cardiol 2008, 51:1073-1079.
24. Abraham W.T. Disease management: remote monitoring in heart failure patients with implantable defibrillators, resynchronization devices, and haemodynamic monitors. Europace 2013, 15(suppl 1):i40-i46.
25. Abraham W.T., Adamson P.B., Bourge R.C., et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011, 377:658-666.
26. Woodlend A.K., Sherrard H., Fraser M., et al. Telehome monitoring in patients with cardiac disease who are at high risk of readmission. Heart Lung 2008, 37:36-45.
27. Burstein H.J., Prestrud A.A., Seidenfeld J., et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. JClin Oncol 2010, 28:3784-3796.
28. de Denus S., Labbe C., Philipps M.S., Tardif J.C., Rioux J.D. Pharmacogenomics. Acute Coronary Syndromes: A companion to Braunwald's Heart Disease 2011, 81-93. Saunder. 2nd ed. P. Theroux (Ed.).
29. de Denus S., Letarte N., Hurlimann T., et al. An evaluation of pharmacists' expectations towards pharmacogenomics. Pharmacogenomics 2013, 14:165-175.
30. Bonter K., Desjardins C., Currier N., Pun J., Ashbury F.D. Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicine. BMJ Open 2011, 1:e000110.
31. Tenori L., Hu X., Pantaleo P., et al. Metabolomic fingerprint of heart failure in humans: a nuclear magnetic resonance spectroscopy analysis. Int J Cardiol 2013, 168:e113-e115.
32. 1H nuclear magnetic resonance based metabolic urinary profiling of patients with ischemic heart failure. Clin Biochem 2011, 44:293-299.
33. Palmieri V., Roman M.J., Bella J.N., et al. Prognostic implications of relations of left ventricular systolic dysfunction with body composition and myocardial energy expenditure: the Strong Heart Study. JAm Soc Echocardiogr 2008, 21:66-71.
34. Shah S.H., Kraus W.E., Newgard C.B. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation 2012, 126:1110-1120.
35. Rhee E.P., Gerszten R.E. Metabolomics and cardiovascular biomarker discovery. Clin Chem 2012, 58:139-147.
36. Du Z., Shen A., Huang Y., et al. 1H-NMR-based metabolic analysis of human serum reveals novel markers of myocardial energy expenditure in heart failure patients. PLoS One 2014, 9:e88102.
37. Felker G.M., Hasselblad V., Hernandez A.F., O'Connor C.M. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009, 158:422-430.
38. Porapakkham P., Porapakkham P., Zimmet H., Billah B., Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 2010, 170:507-514.
39. Masson S., Anand I., Favero C., et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation 2012, 125:280-288.
40. Gravning J., Askevold E.T., Nymo S.H., et al. Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial. Circ Heart Fail 2014, 7:96-103.
41. Ahmad T, Fiuzat M, Pencina MJ, etal. Charting a roadmap for heart failure biomarker studies [e-pub ahead of print]. JACC Heart Fail . Accessed: September 17, 2014. doi:10.1016/j.jchf.2014.02.005.2014.
42. Cheng A., Dalal D., Butcher B., et al. Prospective observational study of implantable cardioverter-defibrillators in primary prevention of sudden cardiac death: study design and cohort description. JAm Heart Assoc 2013, 2:e000083.
43. Mordi I., Jhund P.S., Gardner R.S., et al. LGE and NT-proBNP identify low risk of death or arrhythmic events in patients with primary prevention ICDs. JACC Cardiovasc Imaging 2014, 7:561-569.
44. Karantalis V., Schulman I.H., Hare J.M. Nitroso-redox imbalance affects cardiac structure and function. JAm Coll Cardiol 2013, 61:933-935.
45. Hare J.M., Mangal B., Brown J., et al. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. JAm Coll Cardiol 2008, 51:2301-2309.
46. De Marco T., Chatterjee K., Rouleau J.L., Parmley W.W. Abnormal coronary hemodynamics and myocardial energetics in patients with chronic heart failure caused by ischemic heart disease and dilated cardiomyopathy. Am Heart J 1988, 115:809-815.
47. Mundil D., Cameron-Vendrig A., Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diabetes Vasc Dis Res 2012, 9:95-108.
48. Pitt B., Pfeffer M.A., Assmann S.F., et al. Spironolactone for heart failure with preserved ejection fraction. NEngl J Med 2014, 370:1383-1392.
49. Konstam M.A., Pang P.S., Gheorghiade M. Seeking new heights in acute heart failure syndromes: lessons from ASCEND and EVEREST. Eur Heart J 2013, 34:1345-1349.
50. MacDonald M.R., Petrie M.C., Hawkins N.M., et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008, 29:1224-1240.
51. Maggioni A.P., Dahlstrom U., Filippatos G., et al. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2010, 12:1076-1084.
52. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012, 14:803-869.
53. Barfacker L., Kuhl A., Hillisch A., et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 2012, 7:1385-1403.
54. Pitt B., Kober L., Ponikowski P., et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013, 34:2453-2463.
55. McMurray J.J.V., Packer M., Desai A.S., et al. Angiotensin-neprilysin inhibition versus Enalapril in heart failure. NEngl J Med 2014, 371:993-1004.
56. Paulus W.J., Tschope C. Anovel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. JAm Coll Cardiol 2013, 62:263-271.
57. Pons J., Leblanc M.H., Bernier M., et al. Effects of chronic sildenafil use on pulmonary hemodynamics and clinical outcomes in heart transplantation. JHeart Lung Transplant 2012, 31:1281-1287.
58. Potter B.J., White M., Carrier M., et al. Hemodynamic and clinical benefits associated with chronic sildenafil therapy in advanced heart failure: experience of the Montreal Heart Institute. Can J Cardiol 2012, 28:69-73.
59. Redfield M.M., Chen H.H., Borlaug B.A., et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013, 309:1268-1277.
60. Felker G.M., Benza R.L., Chandler A.B., et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. JAm Coll Cardiol 2003, 41:997-1003.
61. Koniari K., Parissis J., Paraskevaidis I., Anastasiou-Nana M. Treating volume overload in acutely decompensated heart failure: established and novel therapeutic approaches. European heart journal. Acute Cardiovascular Care 2012, 1:256-268.
62. Malik F.I., Hartman J.J., Elias K.A., et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 2011, 331:1439-1443.
63. Cleland J.G., Teerlink J.R., Senior R., et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 2011, 378:676-683.
64. Toischer K., Lehnart S.E., Tenderich G., et al. K201 improves aspects of the contractile performance of human failing myocardium via reduction in Ca2+ leak from the sarcoplasmic reticulum. Basic Res Cardiol 2010, 105:279-287.
65. Kranias E.G., Hajjar R.J. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res 2012, 110:1646-1660.
66. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125:188-197.
67. Solomon S.D., Dobson J., Pocock S., et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007, 116:1482-1487.
68. Massie B.M., O'Connor C.M., Metra M., et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. NEngl J Med 2010, 363:1419-1428.
69. O'Connor C.M., Starling R.C., Hernandez A.F., et al. Effect of nesiritide in patients with acute decompensated heart failure. NEngl J Med 2011, 365:32-43.
70. Chen H.H., Anstrom K.J., Givertz M.M., et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 2013, 310:2533-2543.
71. Mitrovic V., Seferovic P.M., Simeunovic D., et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006, 27:2823-2832.
72. Teichman S.L., Unemori E., Teerlink J.R., Cotter G., Metra M. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep 2010, 7:75-82.
73. Teerlink J.R., Cotter G., Davison B.A., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013, 381:29-39.
74. Mentz R.J., Kjeldsen K., Rossi G.P., et al. Decongestion in acute heart failure. Eur J Heart Fail 2014, 16:471-482.
75. McKelvie R.S., Moe G.W., Ezekowitz J.A., et al. The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure. Can J Cardiol 2013, 29:168-181.
76. DiNicolantonio J.J. Should torsemide be the loop diuretic of choice in systolic heart failure?. Future Cardiol 2012, 8:707-728.
77. Bikdeli B., Strait K.M., Dharmarajan K., et al. Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives?. JAm Coll Cardiol 2013, 61:1549-1550.
78. Felker G.M., Lee K.L., Bull D.A., et al. Diuretic strategies in patients with acute decompensated heart failure. NEngl J Med 2011, 364:797-805.
79. Felker G.M., Mentz R.J. Diuretics and ultrafiltration in acute decompensated heart failure. JAm Coll Cardiol 2012, 59:2145-2153.
80. Gheorghiade M., Konstam M.A., Burnett J.C., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007, 297:1332-1343.
81. Gandhi S., Mosleh W., Myers R.B. Hypertonic saline with furosemide for the treatment of acute congestive heart failure: a systematic review and meta-analysis. Int J Cardiol 2014, 173:139-145.
82. Velazquez E.J., Lee K.L., Deja M.A., et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. NEngl J Med 2011, 364:1607-1616.
83. Panza J.A., Velazquez E.J., She L., et al. Extent of coronary and myocardial disease and benefit from surgical revascularization in LV dysfunction. JAm Coll Cardiol 2014, 64:553-561.
84. Bonow R.O., Maurer G., Lee K.L., et al. Myocardial viability and survival in ischemic left ventricular dysfunction. NEngl J Med 2011, 364:1617-1625.
85. O'Meara E., Mielniczuk L.M., Wells G.A., et al. Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) IMAGE HF Project I-A: study protocol for a randomized controlled trial. Trials 2013, 14:218.
86. Jones R.H., Velazquez E.J., Michler R.E., et al. Coronary bypass surgery with or without surgical ventricular reconstruction. NEngl J Med 2009, 360:1705-1717.
87. Michler R.E., Rouleau J.L., Al-Khalidi H.R., et al. Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. JThorac Cardiovasc Surg 2013, 146:1139-1145.e6.
88. Ducas R.A., White C.W., Wassef A.W., et al. Functional mitral regurgitation: current understanding and approach to management. Can J Cardiol 2014, 30:173-180.
89. Koelling T.M., Aaronson K.D., Cody R.J., Bach D.S., Armstrong W.F. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J 2002, 144:524-529.
90. Seneviratne B., Moore G.A., West P.D. Effect of captopril on functional mitral regurgitation in dilated heart failure: a randomised double blind placebo controlled trial. Br Heart J 1994, 72:63-68.
91. Capomolla S., Febo O., Gnemmi M., et al. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J 2000, 139:596-608.
92. Smith P.K., Michler R.E., Woo Y.J., et al. Design, rationale, and initiation of the Surgical Interventions for Moderate Ischemic Mitral Regurgitation Trial: a report from the Cardiothoracic Surgical Trials Network. JThorac Cardiovasc Surg 2012, 143:111-117. 117.e1.
93. Acker M.A., Parides M.K., Perrault L.P., et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. NEngl J Med 2014, 370:23-32.
94. Feldman T., Foster E., Glower D.D., et al. Percutaneous repair or surgery for mitral regurgitation. NEngl J Med 2011, 364:1395-1406.
95. Machaalany J., Bilodeau L., Hoffmann R., et al. Treatment of functional mitral valve regurgitation with the permanent percutaneous transvenous mitral annuloplasty system: results of the multicenter international Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients with Heart Failure trial. Am Heart J 2013, 165:761-769.
96. van Bommel R.J., Marsan N.A., Delgado V., et al. Cardiac resynchronization therapy as a therapeutic option in patients with moderate-severe functional mitral regurgitation and high operative risk. Circulation 2011, 124:912-919.
97. Elmariah S., Palacios I.F., McAndrew T., et al. Outcomes of transcatheter and surgical aortic valve replacement in high-risk patients with aortic stenosis and left ventricular dysfunction: results from the Placement of Aortic Transcatheter Valves (PARTNER) trial (cohort A). Circ Cardiovasc Interv 2013, 6:604-614.
98. Parkash R., Philippon F., Shanks M., et al. Canadian Cardiovascular Society guidelines on the use of cardiac resynchronization therapy: implementation. Can J Cardiol 2013, 29:1346-1360.
99. Chung E.S., Leon A.R., Tavazzi L., et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008, 117:2608-2616.
100. Yu C.M., Hayes D.L. Cardiac resynchronization therapy: state of the art 2013. Eur Heart J 2013, 34:1396-1403.
101. Acomparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. NEngl J Med 1997, 337:1576-1583.
102. Connolly S.J., Gent M., Roberts R.S., et al. Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000, 101:1297-1302.
103. Kuck K.H., Cappato R., Siebels J., Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000, 102:748-754.
104. Moss A.J., Zareba W., Hall W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. NEngl J Med 2002, 346:877-883.
105. Moss A.J., Hall W.J., Cannom D.S., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. NEngl J Med 1996, 335:1933-1940.
106. Buxton A.E., Lee K.L., Fisher J.D., Josephson M.E., Prystowsky E.N., Hafley G. Arandomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. NEngl J Med 1999, 341:1882-1890.
107. Kinch Westerdahl A., Sjoblom J., Mattiasson A.C., Rosenqvist M., Frykman V. Implantable cardioverter-defibrillator therapy before death: high risk for painful shocks at end of life. Circulation 2014, 129:422-429.
108. Bohm M., Ewen S., Linz D., et al. Therapeutic potential of renal sympathetic denervation in patients with chronic heart failure. EuroIntervention 2013, 9(suppl R):R122-R126.
109. Davies J.E., Manisty C.H., Petraco R., et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol 2013, 162:189-192.
110. Gronda E., Seravalle G., Brambilla G., et al. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study. Eur J Heart Fail 2014, 16:977-983.
111. Anversa P., Capasso J.M., Sonnenblick E.H., Olivetti G. Mechanisms of myocyte and capillary growth in the infarcted heart. Eur Heart J 1990, 11(suppl B):123-132.
112. Anversa P., Sonnenblick E.H. Ischemic cardiomyopathy: pathophysiologic mechanisms. Prog Cardiovasc Dis 1990, 33:49-70.
113. Behfar A., Crespo-Diaz R., Terzic A., Gersh B.J. Cell therapy for cardiac repair-lessons from clinical trials. Nat Rev Cardiol 2014, 11:232-246.